

paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please add the following new claims:

Sub F1 → 127. (New) The composition of claim 92, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

128. (New) The composition of claim 127, wherein said human albumin is lipid-poor human albumin.

e1 129. (New) The composition of claim 92, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

130. (New) The composition of claim 129, wherein said human transferrin is iron-saturated human transferrin.

131. (New) The product of manufacture of claim 98, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

132. (New) The product of manufacture of claim 131, wherein said human albumin is lipid-poor human albumin.

133. (New) The product of manufacture of claim 98, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

134. (New) The product of manufacture of claim 133, wherein said human transferrin is iron-saturated human transferrin.

135. (New) The product of manufacture of claim 101, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

e1
Cont
136. (New) The product of manufacture of claim 135, wherein said human albumin is lipid-poor human albumin.

137. (New) The product of manufacture of claim 101, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

138. (New) The product of manufacture of claim 137, wherein said human transferrin is iron-saturated human transferrin.

139. (New) The method of claim 105, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

140. (New) The method of claim 139, wherein said human albumin is lipid-poor human albumin.

141. (New) The method of claim 105, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

142. (New) The method of claim 141, wherein said human transferrin is iron-saturated human transferrin.

143. (New) The method of claim 108, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

144. (New) The method of claim 143, wherein said human albumin is lipid-poor human albumin.

145. (New) The method of claim 108, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

146. (New) The method of claim 145, wherein said human transferrin is iron-saturated human transferrin.

147. (New) The method of claim 117, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

Ex
Cont

148. (New) The method of claim 147, wherein said human albumin is lipid-poor human albumin.

149. (New) The method of claim 117, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

150. (New) The method of claim 149, wherein said human transferrin is iron-saturated human transferrin.

151. (New) The method of claim 122, wherein said serum-free eukaryotic cell culture medium supplement comprises human albumin.

el
Amf

152. (New) The method of claim 151, wherein said human albumin is lipid-poor human albumin.

153. (New) The method of claim 122, wherein said serum-free eukaryotic cell culture medium supplement comprises human transferrin.

154. (New) The method of claim 153, wherein said human transferrin is iron-saturated human transferrin.
